Health Observance

The promise of AI in precision medicine and immunotherapy for diabetes

Today is World Diabetes Day
Opeoluwa Iwaloye
By Opeoluwa Iwaloye
Nov. 14, 2023

Robust datasets and computer algorithms are merged in the expanding field of artificial intelligence to tackle problems that humans typically solve. Healthcare is one area in which AI has taken hold.

Today is World Diabetes Day. To mark this observance, this article covers the many ways in which diabetes research and drug development stands to benefit from the use of AI.

About the condition

According to the World Health Organization, about 422 million people have diabetes, and that number increases each year.

Diabetes is a consequence of insulin deficiency, resulting in uncontrolled blood glucose. Symptoms include increased thirst, frequent urination, fatigue, blurred vision and slow healing wounds. (For more about the condition, see box below.)

Precision medicine

Precision medicine is an approach that aims to optimize the prevention, diagnosis, prediction and treatment of conditions by integrating big data and accounting for individual differences based on unique genetic, environmental and lifestyle factors. Precision medicine promises to reduce healthcare costs and improve outcomes.

AI plays a pivotal role in enabling precision medicine for diabetes in the following ways:

  1. Genomic analysis: Scientists can use AI-driven algorithms to analyze vast genomic data sets, identifying genetic markers and mutations associated with diabetes subtypes.

  2. Early predictive diagnosis: AI models can predict an individual’s risk of developing diabetes by analyzing their unique genetics, family histories and lifestyles. These predictions enable early diagnosis, intervention and preventive measures.

  3. Personalized treatment options: AI can be used to analyze data collected from individuals — such as glucose levels, response to treatment and lifestyle changes — to develop personalized treatment options tailored to each individual's unique needs.


Immunotherapy exploits the immune system to fight diseases. It has been extensively researched for diabetes treatment. AI has the potential to accelerate research, discovery and development of immunotherapy strategies for diabetes in the following ways:

  1. Drug discovery: AI-powered algorithms can search through existing large databases of chemical compounds to identify potential immunotherapeutic. Also, it can be used to improve clinical trial design and optimization through predictions of drug dosages and efficacy.

  2. Personalized immunotherapies: Large amounts of data are generated from flow cytometry and other immunophenotyping techniques in diabetes research. AI can analyze big immunophenotypic profiles in individuals to identify biomarkers and other factors, allowing for more rapid development of personalized and effective treatments.

To exploit AI in diabetes research, scientists need access to large-scale datasets, including patient records, genetic information, experimental data and clinical trial results. These data would provide AI algorithms with robust information to identify patterns, correlations and treatment opportunities that might not be apparent to human researchers. If we had to examine these datasets with human capacity, it would take an enormous amount of effort and time. As noted by Guan et al. 2023 "The application of AI in diabetes care and research offers substantial benefits for basic biomedical research, translational sciences, and clinical practice.

It is important to mention that the integration of AI into diabetes research does have challenges, such as concerns with handling sensitive patient data, the need for robust regulatory frameworks and the potential for algorithmic bias.

Regardless, artificial intelligence has the potential to transform the lives of millions of individuals living with diabetes. As researchers continue to embrace AI in diabetes research and we observe World Diabetes Day, we can dream of a future when this condition is managed and treated with unprecedented precision and efficacy, offering renewed hope for patients and their families.

More about diabetes

There are three main types of the condition.

  • Type 1 is an autoimmune disease in which beta cells are dysfunctional. The body does not make insulin or makes too little insulin, resulting in hyperglycemia. It is currently managed through the exogenous administration of insulin.
  • In Type 2, the beta cells are functional, but the pancreas is not making enough insulin, or the body is not using insulin properly, resulting in insulin resistance. It can be managed through lifestyle changes and medications.
  • Gestational diabetes develops during pregnancy and usually resolves after the baby is born, however it increases the risk of developing Type 2 diabetes later in life.
A patient wears a continuous glucose monitor.

People living with diabetes need insulin. A major challenge is the lack of availability of insulin in low-income countries. In parts of the world in which it is available, it can be very expensive.

The matter of cost has become an ongoing conversation on X/Twitter using hashtag #insulin4all. One user recently posted: “Trying to afford my insulin before meeting my deductible is, hands down, the most stressful thing I’ve ever experienced in my life. I don’t want to do this forever.”

In addition, there is variability in clinical presentation, progression and response to insulin and other medications among individuals with diabetes.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Opeoluwa Iwaloye
Opeoluwa Iwaloye

Opeoluwa Iwaloye is a Ph.D. student at the University of Florida Biomedical Sciences Program (immunology and microbiology) studying the genetic and environmental determinants of Type 1 diabetes. She is passionate about the molecular basis of immunological diseases.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Opinions

Opinions highlights or most popular articles

One on one: A Discover BMB mentoring experiment
Annual Meeting

One on one: A Discover BMB mentoring experiment

Dec. 7, 2023

Over three afternoons during the ASBMB meeting in Seattle, 38 mentors offered guidance in 103 half-hour appointments booked by 88 mentees.

What we lost: Two early-career researchers share their pandemic experiences

What we lost: Two early-career researchers share their pandemic experiences

Nov. 30, 2023

“We have learned the immense importance of having an unswerving mentor, a supportive institution and an understanding civil society … We are determined to bounce back with vigor and passion.”

NIH diversity supplements offer a pathway to independence

NIH diversity supplements offer a pathway to independence

Nov. 29, 2023

These funding mechanisms have been underutilized. The ASBMB public affairs staff offers recommendations to change that.

10 tips to get you through your Ph.D. program

10 tips to get you through your Ph.D. program

Nov. 29, 2023

“All of us who have survived graduate school share a bond,” Danielle Guarracino writes. “In that spirit, here’s some advice.”

The inside scoop on NSF fellowships

The inside scoop on NSF fellowships

Nov. 28, 2023

National Science Foundation program directors share how grad students and postdocs can secure coveted funds.

A chapter builds connections
Student Chapters

A chapter builds connections

Nov. 27, 2023

The ASBMB helped Lauryn Ridley build a community among her peers: “It’s outside the classroom, and you can be free to relate to other people who are going through the same things that you’re going through.”